Last reviewed · How we verify
NCT06724120
Artificial Intelligence Prognostic Model for Sepsis Based on Time Series Analysis
trial testing No interventions in Sepsis in 3,641 participants. Completed in 31 December 2023.
31 December 2023
Quick facts
| Lead sponsor | West China Hospital |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 3,641 |
| Start date | 1 January 2020 |
| Primary completion | 31 December 2023 |
| Estimated completion | 31 December 2023 |
| Sites | 1 location across China |
Drugs / interventions tested
- No interventions — full drug profile →
Conditions studied
- Sepsis — all drugs for Sepsis →
- Prognostic Model — all drugs for Prognostic Model →
- Artificial Intelligence — all drugs for Artificial Intelligence →
- Individuality — all drugs for Individuality →
Sponsor
West China Hospital
Who can join
18 and older, any sex, with Sepsis or Prognostic Model. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Sepsis is a life-threatening organ dysfunction caused by a dysregulated host response to infection. It is one of the leading causes of death and disability worldwide, with an inpatient mortality rate of 10-20%. Sepsis is a severe complication in critically ill patients and can lead to septic shock and multiple organ dysfunction syndrome (MODS), usually triggered by severe trauma, surgery, and infections. Despite the availability of advanced diagnostic, therapeutic, and monitoring technologies, the incidence and mortality of sepsis remain high, posing a significant global challenge to the medical community. Over 49 million people worldwide develop sepsis annually, with approximately 11 million deaths, resulting in a mortality rate of about 15%-25%. This study aims to develop a prognosis prediction model for sepsis patients using a neural network architecture (Transformer algorithm), based on time-series data. The primary outcome observed is the mortality outcome of sepsis patients. The goal of the research is to enhance the early identification of high-risk sepsis patients, thereby optimizing the timing of sepsis treatment and intervention and improving the accuracy of prognosis prediction for sepsis patients.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06724120
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of No interventions
Trials testing the same drug.
- NCT07497815 — Artificial Intelligence-assisted Diagnosis in Ophthalmology · not yet recruiting
- NCT07509632 — Predicting Pathological Complete Response in Rectal Cancer Using Machine Learning · active not recruiting
- NCT07307040 — Precision Diabetes Management: Integrated East-West Approach · not yet recruiting
- NCT07276945 — Individualized Early Diagnosis and Treatment System of Gestational Diabetes Mellitus (GDM) Based on New Continuous Gluco · not yet recruiting
- NCT06999681 — Postoperative Arrhythmia and Preoperative Cardiac Function · not yet recruiting
Other recruiting trials for Sepsis
Currently open trials in the same condition.
- NCT07507877 — Infraclavicular Axillary Vein Collapsibility Index as a Predictor of Fluid Responsiveness · recruiting
- NCT07154615 — Assessing Immune Dysfunction in Sepsis · recruiting
- NCT07419802 — OxiCLEAR (Oxiris Cytokines and Endotoxin Adsorption Rate) Study · recruiting
- NCT07351344 — African Survey on Sepsis Knowledge (ASK) · recruiting
- NCT07448805 — Accuracy and Safety of the Syai Tag System for Continuous Glucose Monitoring in Intensive Internal Care Unit · NA · recruiting
Other West China Hospital trials
Trials by the same sponsor.
- NCT07583654 — Safety, Tolerability, and Preliminary Antitumor Activity of Cationic Peptide-IL22BP mRNA in Advanced Solid Tumors · Phase 1 · not yet recruiting
- NCT07583914 — Safety, Tolerability, and Preliminary Antitumor Activity of Non-Cationic Peptide-CD47 siRNA in Advanced Solid Tumors · Phase 1 · not yet recruiting
- NCT07492914 — Neoadjuvant Sacituzumab Govitecan Plus Tagitanlimab for Resectable Head and Neck Squamous Cell Carcinoma · Phase 2 · recruiting
- NCT07507097 — Study on the Optimal Head Position for Patients With Severe Acute Ischemic Stroke · NA · not yet recruiting
- NCT07472933 — Vebotolimab Combined With Ptorlimab for EGFR-positive Refractory Advanced Biliary Tract Malignancies · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06724120 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by West China Hospital
- Last refreshed: 9 December 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06724120.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing